Asia PR News

INDIANAPOLIS, Jan. 31 /PRNewswire-AsiaNet/ –

Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical
Company, (NYSE: DOW), announced today that it has received the world’s first
regulatory approval for a plant-made vaccine from the United States Department
of Agriculture (USDA) Center for Veterinary Biologics. This approval represents
an innovative milestone for the company and the industry.

"With this achievement Dow AgroSciences is revolutionizing the field of
preventative medicine with plant-cell-produced vaccines," said Butch Mercer,
Dow AgroSciences’ global business leader for Animal Health.

The Dow AgroSciences Concert(TM) Plant-Cell-Produced System represents a
new category of plant-made vaccines. This leading edge technology utilizes
plant cells instead of whole plants in a secure, bio-contained environment to
produce vaccines. Because of this bio-contained production system, concerns
and challenges associated with making vaccines in whole plants or food crops
are eliminated.

"Being the first company to ever register a plant-made vaccine is another
example of Dow AgroSciences’ cutting edge approach to bringing highly novel
and differentiated solutions to the market," said Jerome Peribere, Dow
AgroSciences’ president and CEO.

The Concert(TM) Plant-Cell-Produced System uses only the necessary parts
of the disease causing agent to stimulate immunity in a manufacturing process
that is totally free of animal components. According to John Cuffe, Dow
AgroSciences’ R&D leader for Animal Health, "This approval is a perfect
example of how biotechnology is advancing science by creating a new category
of vaccines that is both safe and effective."

By achieving this regulatory milestone, Dow AgroSciences has demonstrated
that this new technology fits within the existing USDA Center for Veterinary
Biologics regulatory approval process. Dow AgroSciences can now focus its
efforts on developing new, innovative vaccines with an emphasis on animal
health. Possible target animals include: horses, companion animals (such as
dogs and cats), poultry, swine, and cattle. Furthermore, utilizing this
revolutionary technology for human diseases is a real possibility.

This milestone achievement by Dow AgroSciences was the result of effective
collaborations with prominent organizations and institutions including
Washington University, Boyce Thompson Institute for Plant Research, Benchmark
Biolabs, Inc., and The Biodesign Institute at Arizona State University. In
less than five years Dow AgroSciences moved the science forward, established a
production facility, and received this regulatory approval.

Dow AgroSciences is growing through an ambitious program of scientific
discovery that creates new, revolutionary solutions. The Concert(TM)
Plant-Cell-Produced System demonstrates how Dow AgroSciences is applying
innovation to safely put the power of prevention to work.

About Dow AgroSciences LLC
Dow AgroSciences LLC, based in Indianapolis, Indiana, USA, is a global
leader in providing pest management, agricultural seed and biotechnology
products that improve the quality and quantity of the earth’s food supply and
contribute to the health and quality of life of the world’s growing
population. Dow AgroSciences has approximately 5,500 people in more than 50
countries dedicated to its business, and has worldwide sales of US $3.4
billion. Dow AgroSciences is a wholly owned subsidiary of The Dow Chemical
Company. For more information about Dow AgroSciences, visit
http://www.dowagro.com

(TM)Trademark of Dow AgroSciences LLC

SOURCE: Dow AgroSciences LLC

CONTACT: Robyn Heine,
Dow AgroSciences,
+1-317-337-4807, or
rheine@dow.com

FCMN Contact:
mhancock@dow.com

Web site: http://www.dowagro.com

(DOW)